Highlights

  • PharmX (ASX:PHX) closed at AUD 0.10 on 18 August 2026, up 2.04%.
  • S&P/ASX 200 Info Tech (ASX:XIJ) closed at 1,956.80 points, down 1.02% today.
  • PharmX Marketplace monthly GTV exceeded $1.3 million in March 2026.
  • Platform connects more than 7,000 pharmacies representing around $23 billion in GTV.

PharmX Technologies Limited (ASX:PHX) closed at AUD 0.10 on 18 August 2026, increasing 2.04% during the trading session. The movement occurred during a weaker session for technology stocks, with investors assessing developments across healthcare technology, pharmacy Supply chain digitisation and the company’s Marketplace expansion.

The broader Australian market recorded lower trading levels, with the S&P/ASX 200 (ASX:XJO) closing at 9,070.00 points, down 0.035% today, while the S&P/ASX 300 (ASX:XKO) closed at 9,004.90 points, down 0.037% today.

The S&P/ASX 200 Info Tech (ASX:XIJ) closed at 1,956.80 points, down 1.02% today.

A daily share price movement does not necessarily indicate a change in a company’s underlying fundamentals. Investors generally assess platform adoption, transaction volumes, supplier growth, pharmacy engagement, strategic partnerships and Recurring Revenue opportunities when reviewing technology businesses.

Digital pharmacy infrastructure platform

PharmX operates a digital ordering and connectivity platform that links pharmacies, wholesalers, suppliers and technology providers across Australia and New Zealand.

The company provides electronic ordering, e-invoicing, analytics and pharmacy supply chain solutions. Its platform is designed to improve efficiency across pharmacy procurement by connecting participants through a centralised digital infrastructure network.

PharmX’s Business model is based on transaction processing, connectivity services, platform fees and digital marketplace activity. Investors generally monitor pharmacy adoption, supplier participation, transaction volumes, gross transaction value (GTV), platform utilisation and Partnership development.

The company’s Marketplace platform represents an expansion from traditional ordering infrastructure towards a broader digital commerce model, allowing pharmacies to access products from multiple suppliers through a single platform.

Q3 FY26 update and Sigma partnership progress

PharmX released its Q3 FY26 Investor Update on 5 May 2026, highlighting strategic and commercial progress following its alliance with Sigma Healthcare Limited. The company reported that PharmX is the preferred EDI and growth partner for Sigma Wholesale and Chemist Warehouse retail operations across Australia and New Zealand.

During Q3 FY26, PharmX Marketplace recorded monthly GTV above $1.3 million in March 2026, with GTV growth of 57% during the quarter. The company reported that April 2026 Marketplace GTV exceeded the March record by 42%.

PharmX reported that the Marketplace annualised GTV run rate was expected to exceed $100 million within 12 months, supported by supplier expansion, pharmacy adoption and increased platform engagement.

The company expanded its supplier network during the period, including the addition of approximately 5,000 health food and complementary medicine products from ParagonCare Complementary Medicines. PharmX also continued expanding its Customer Success function to support pharmacy engagement and platform adoption.

Earlier in H1 FY26, PharmX reported revenue of AUD 3.9 million, up 3% compared with H1 FY25. Marketplace revenue increased 24%, Gateway revenue increased 5%, and New Zealand revenue increased 54%. The company reported positive EBITDA of AUD 0.5 million and gross Margin of 84%.

The H1 FY26 update also highlighted the Sigma strategic alliance, under which Sigma subscribed for approximately 59.95 million PharmX shares, representing an initial strategic Equity interest, alongside the renewal of Sigma’s wholesale EDI agreement.

Factors investors generally monitor

For PharmX, Marketplace adoption remains a key operating measure. Investors monitor pharmacy registrations, supplier participation, order frequency and GTV growth to assess platform scale.

Transaction Volume growth is another important factor. Digital marketplaces generally rely on increasing activity levels across buyers and suppliers to expand revenue opportunities.

The Sigma partnership is a major strategic focus. Investors assess how the relationship contributes to pharmacy coverage, supplier connectivity, platform utilisation and future commercial opportunities.

Supplier expansion remains important because a broader product catalogue can improve platform value for pharmacies. Investors monitor new supplier additions, product availability and customer engagement.

Technology Investment is another consideration. PharmX operates infrastructure that supports pharmacy ordering, inventory management and digital supply chain connectivity, requiring ongoing platform development.

Healthcare technology competition is also monitored. Investors assess PharmX’s ability to maintain its position within pharmacy technology infrastructure while expanding its digital marketplace offering.

Understanding the share price movement

PharmX shares increased 2.04% on 18 August 2026, reflecting trading activity during the session. Short-term share price movements can occur due to investor sentiment, sector trends, market positioning and expectations around future growth.

A single trading day’s movement does not independently confirm a change in the company’s operational performance or financial outlook. Investors generally review platform growth, transaction activity, strategic partnerships and commercial execution when assessing technology companies.

For PharmX, investor attention remains focused on Marketplace scaling, Sigma alliance opportunities, supplier growth and conversion of platform activity into revenue.

Healthcare technology sector outlook

Healthcare technology continues evolving as industries seek digital infrastructure that improves efficiency, connectivity and data management.

Technology providers supporting healthcare supply chains are generally assessed on their ability to connect fragmented markets, improve workflow efficiency and build scalable platforms.

PharmX’s pharmacy network provides exposure to the digitisation of healthcare procurement and supply chain management. However, future performance remains influenced by adoption rates, supplier participation, competitive conditions and execution of strategic initiatives.

Investor focus is likely to remain on Marketplace growth, GTV expansion, pharmacy engagement, supplier partnerships and the long-term development of the company’s digital infrastructure platform.

Conclusion

PharmX (ASX:PHX) closed at AUD 0.10 on 18 August 2026, up 2.04% during the session. The company continues developing a digital pharmacy technology platform connecting pharmacies, suppliers and wholesalers across Australia and New Zealand.

The Q3 FY26 update highlighted Marketplace GTV exceeding $1.3 million in March 2026, a 42% increase in April GTV compared with March, and continued progress under the Sigma strategic alliance. The H1 FY26 update reported AUD 3.9 million in revenue and positive EBITDA of AUD 0.5 million. While daily share price movements reflect market activity, they do not alone indicate changes in underlying business fundamentals. Investors continue to monitor platform adoption, supplier growth, transaction volumes and commercial execution.